Sept. 17-20, 2011
TheBodyPRO.com's independent coverage of ICAAC 2011 is not associated with the conference itself. Please note that all links on this page will take you to articles on TheBodyPRO.com, TheBody.com's sister site for health care professionals.
TheBodyPRO.com is an independent website not associated with this conference.
Earlier this year, biopharmaceutical firm Sangamo BioSciences, Inc., made waves (and had many people prematurely uttering the word "cure") when it offered data on a form of gene therapy that attempts to rewire an HIV-infected person's CD4+ cells so they no longer have a properly working CCR5 receptor. Those earlier data pretty much said, "There's a chance this thing might actually work." Further results presented here at ICAAC 2011 say, "Seriously, there's still a chance this thing might actually work."
More Top Stories:
The 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2011) is expected to draw approximately 11,000 attendees (most of them clinicians and researchers) from throughout the world to present and discuss the latest developments in infectious disease etiology, epidemiology and clinical management. Although it is not an HIV-specific conference, studies on HIV and related complications/coinfections often make up a significant proportion of presented research.
TheBodyPRO.com's coverage of ICAAC 2011 will include summaries of individual studies and presentations, as well as discussions featuring study authors and leading HIV clinicians/researchers.
In addition to checking this page for the latest updates, be sure to follow @TheBodyDotCom and our editorial director @MylesatTheBody on Twitter for bite-sized recaps and analyses of breaking research from the conference.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|